<DOC>
	<DOCNO>NCT02341534</DOCNO>
	<brief_summary>The BIO|GUARD-MI study investigate whether continuous arrhythmia monitoring consequent treatment detect arrhythmias patient acute myocardial infarction preserve cardiac function , risk factor , decrease risk major adverse cardiac event .</brief_summary>
	<brief_title>BIO monitorinG Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction</brief_title>
	<detailed_description>Patients randomize BioMonitor arm receive implantable cardiac monitor ( ICM ; BioMonitor ) remote monitor function ( Home Monitoring® ) . If device detects report arrhythmia , patient appropriately examine treat . Patients randomize control arm receive best proven treatment , implantable cardiac monitor .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>History AMI accord guideline CHADS2score ≥ 3 modify agevariable ≥ 65 year LVEF &gt; 35 % estimate echocardiography within 6 month enrollment conclusion AMI treatment Patient accept activation Home Monitoring® Patient provide write informed consent Platelet count &lt; 90.000 per mm3 patient haemorrhagic diathesis Permanent oral anticoagulation treatment atrial fibrillation Indication chronic renal dialysis Pacemaker ICD implant indication implantation Previously document sustain VT Parkinson 's disease Life expectancy &lt; 1 year Participation another interventional clinical investigation Female patient pregnant breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>